Department of Pharmaceutics, School of Pharmacy & Technology Management, SVKM'S NMIMS Deemed-to-be University, Shirpur, Maharashtra, 425405, India.
Curr Pharm Biotechnol. 2024;25(4):434-447. doi: 10.2174/1389201024666230519103330.
Cubosomes are a kind of nanoparticle that is distinct from solid particles in that they are liquid crystalline particles formed by self-assembly of a certain surfactant with a current water ratio. Their unique properties as a result of their microstructure are useful in practical applications. Cubosomes, specifically lyotropic nonlamellar liquid crystalline nanoparticles (LCNs) have gained acceptance as a medication delivery strategy for cancer and other disorders. Cubosomes are produced by the fragmentation of a solid-like phase into smaller particles. Because of its particular microstructure, which is physiologically safe and capable of allowing for the controlled release of solubilized compounds, cubic phase particles are garnering considerable attention. These cubosomes are highly adaptable carriers with promising theranostic efficacy because they can be given orally, topically, or intravenously. Throughout its operation, the drug delivery system regulates the loaded anticancer bioactive's target selectivity and drug release characteristics. This compilation examines recent advances and obstacles in the development and application of cubosomes to treat various cancers, as well as the challenges of turning it into a potential nanotechnological invasion.
立方纳米载体是一种纳米粒子，与固体颗粒不同，它们是由一定的表面活性剂在当前水比下自组装形成的液晶颗粒。由于其微观结构的独特性质，它们在实际应用中很有用。立方纳米载体，特别是溶致非层状液晶纳米颗粒（LCN），已被接受为癌症和其他疾病的药物输送策略。立方纳米载体是通过将固态相破碎成较小的颗粒而产生的。由于其特殊的微观结构，生理上安全，并能够控制溶解化合物的释放，立方相颗粒引起了相当大的关注。这些立方纳米载体是具有良好治疗效果的高度适应性载体，因为它们可以口服、局部或静脉给予。在整个操作过程中，药物输送系统调节负载抗癌生物活性物质的靶向选择性和药物释放特性。本综述考察了立方纳米载体在治疗各种癌症方面的开发和应用的最新进展和障碍，以及将其转化为潜在的纳米技术入侵的挑战。
